1rarebird
03-06-2012, 06:25 AM
Ann Oncol. (http://www.ncbi.nlm.nih.gov/pubmed/22377561?dopt=Abstract#) 2012 Feb 29. [Epub ahead of print]
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study.
Georgoulias V (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Georgoulias%20V%22%5BAuthor%5D), Bozionelou V (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bozionelou%20V%22%5BAuthor%5D), Agelaki S (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Agelaki%20S%22%5BAuthor%5D), Perraki M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Perraki%20M%22%5BAuthor%5D), Apostolaki S (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Apostolaki%20S%22%5BAuthor%5D), Kallergi G (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kallergi%20G%22%5BAuthor%5D), Kalbakis K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kalbakis%20K%22%5BAuthor%5D), Xyrafas A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xyrafas%20A%22%5BAuthor%5D), Mavroudis D (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mavroudis%20D%22%5BAuthor%5D).
Source
Department of Medical Oncology, University Hospital of Heraklion, Heraklion.
Abstract
BACKGROUND:
Since the detection of circulating tumor cells (CTCs), which express that human epidermal growth factor receptor 2 (HER2) is an adverse prognostic factor in early breast cancer patients, we investigated the effect of trastuzumab on patients' clinical outcome.
PATIENTS AND METHODS:
Seventy-five women with HER2-negative breast cancer and detectable CK19 messenger RNA (mRNA)-positive CTCs before and after adjuvant chemotherapy were randomized to receive either trastuzumab (n = 36) or observation (n = 39). CK19 mRNA-positive CTCs were detected by RT-PCR and double-stained CK-positive/HER2-positive cells by immunofluorescence. The primary end point was the 3-year disease-free survival rate.
RESULTS:
Fifty-one (89%) of the 57 analyzed patients had HER2-expressing CTCs. After trastuzumab administration, 27 of 36 (75%) women became CK19 mRNA negative compared with 7 of 39 (17.9%) in the observation arm (P = 0.001). After a median follow-up time of 67.2 months, 4 (11%) and 15 (38%) relapses were observed in the trastuzumab and observation arm, respectively (P = 0.008); subgroup analysis indicated that this effect was mainly confined to women with more than three involved axillary lymph nodes (P = 0.004). The median DFS was also significantly higher for the trastuzumab-treated patients (P = 0.008).
CONCLUSION:
Administration of trastuzumab can eliminate chemotherapy-resistant CK19 mRNA-positive CTCs, reduce the risk of disease recurrence and prolong the DFS.
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study.
Georgoulias V (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Georgoulias%20V%22%5BAuthor%5D), Bozionelou V (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bozionelou%20V%22%5BAuthor%5D), Agelaki S (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Agelaki%20S%22%5BAuthor%5D), Perraki M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Perraki%20M%22%5BAuthor%5D), Apostolaki S (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Apostolaki%20S%22%5BAuthor%5D), Kallergi G (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kallergi%20G%22%5BAuthor%5D), Kalbakis K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kalbakis%20K%22%5BAuthor%5D), Xyrafas A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xyrafas%20A%22%5BAuthor%5D), Mavroudis D (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mavroudis%20D%22%5BAuthor%5D).
Source
Department of Medical Oncology, University Hospital of Heraklion, Heraklion.
Abstract
BACKGROUND:
Since the detection of circulating tumor cells (CTCs), which express that human epidermal growth factor receptor 2 (HER2) is an adverse prognostic factor in early breast cancer patients, we investigated the effect of trastuzumab on patients' clinical outcome.
PATIENTS AND METHODS:
Seventy-five women with HER2-negative breast cancer and detectable CK19 messenger RNA (mRNA)-positive CTCs before and after adjuvant chemotherapy were randomized to receive either trastuzumab (n = 36) or observation (n = 39). CK19 mRNA-positive CTCs were detected by RT-PCR and double-stained CK-positive/HER2-positive cells by immunofluorescence. The primary end point was the 3-year disease-free survival rate.
RESULTS:
Fifty-one (89%) of the 57 analyzed patients had HER2-expressing CTCs. After trastuzumab administration, 27 of 36 (75%) women became CK19 mRNA negative compared with 7 of 39 (17.9%) in the observation arm (P = 0.001). After a median follow-up time of 67.2 months, 4 (11%) and 15 (38%) relapses were observed in the trastuzumab and observation arm, respectively (P = 0.008); subgroup analysis indicated that this effect was mainly confined to women with more than three involved axillary lymph nodes (P = 0.004). The median DFS was also significantly higher for the trastuzumab-treated patients (P = 0.008).
CONCLUSION:
Administration of trastuzumab can eliminate chemotherapy-resistant CK19 mRNA-positive CTCs, reduce the risk of disease recurrence and prolong the DFS.